Prem Shankar Misra, V. Ravichandiran, M. Vijey Aanandhi
Prem Shankar Misra1, V. Ravichandiran2, M. Vijey Aanandhi3*
1Research Scholar, Department of Pharmaceutical Chemistry and Analysis, Vels University, (VISTAS), Chennai- 600117, Tamilnadu, India.
2NIPER, Kolkata, India.
3Department of Pharmaceutical Chemistry and Analysis, Vels University (VISTAS),
Chennai- 600117. Tamilnadu, India.
Volume - 10,
Issue - 8,
Year - 2017
A novel series of N-carbamoyl-6-oxo-1-phenyl-1, 6-dihydropyridine-3-carboxamide derivatives (A1-A6) were synthesized by various substitution and their structures were confirmed by spectral and elemental analyses. The cytotoxic activity of the newly synthesized compounds was docked against fibroblast growth factor 1 (FGF1). These FGFR cascades play crucial roles in tumor cell proliferation, angiogenesis, migration, and survival. FGFRs were also identified in a variety of human cancers such as ovarian cancer, myeloproliferative syndromes, lymphomas, prostate and breast cancers as well as other malignant diseases. The molecular docking study was used for confirming their interaction with fibroblast growth factor 1. Thorough in silico molecular docking study, the result showed that all synthesized derivatives (A1-A6) have low binding energy (Table 1) and have good affinity toward their active pocket. Thus the synthesized derivatives considered as good anti cancer agents.
Cite this article:
Prem Shankar Misra, V. Ravichandiran, M. Vijey Aanandhi. Design, Synthesis and In Silico Molecular Docking Study of N-carbamoyl-6-oxo-1-phenyl-1, 6-dihydropyridine-3-carboxamide derivatives as Fibroblast growth factor 1 inhibitor. Research J. Pharm. and Tech. 2017; 10(8): 2527-2534. doi: 10.5958/0974-360X.2017.00447.4